Marie Aliette Dommergues
A5077661397- Respiratory viral infections research
- Pneumonia and Respiratory Infections
- Bacterial Infections and Vaccines
- Pneumocystis jirovecii pneumonia detection and treatment
- Antibiotic Resistance in Bacteria
- Urinary Tract Infections Management
- Pediatric Urology and Nephrology Studies
- Streptococcal Infections and Treatments
Centre Hospitalier de Versailles
2014-2021
Société Française de Cardiologie
2014-2021
Background. Pneumococcal serotypes 1, 3, 5, 7F, and 19A were the most implicated in community-acquired pneumonia (CAP) after implementation of 7-valent pneumococcal conjugate vaccine (PCV7). In France, switch from PCV7 to 13-valent (PCV13) occurred June 2010. An active surveillance network was set up analyze impact PCV13 on CAP.
Abstract We describe here changes in the bacterial causes of pleural empyema before and after implementation 13-valent pneumococcal conjugate vaccine (PCV13) program France (2009–2017). For 220 (39.3%) 560 children, a cause was found. The frequency infection decreased during study from 79.1% 2009 to 36.4% 2017 (P < .001). Group A streptococcus is now leading documented (45.5%).
Objectives We need studies assessing therapeutic options for oral relay in febrile urinary tract infection (FUTI) due to ESBL–producing Enterobacteriaceae (ESBL-E) children. Amoxicillin-clavulanate/cefixime (AC-cefixime) combination seems be a suitable option. sought describe the risk of recurrence at 1 month after end treatment FUTI ESBL-E according therapy used. Materials and methods retrospectively identified children <18 years who were included previous prospective observational...